Most people taking drugs do not know anything about the drug they take. The length of trial wasn't the detail being pointed out. It is the lack of patients. When they have a trial with 3000 people andore than 500 stay on it...then we can talk. Right now they have a trial with a failed primary endpoint and only a few people who haven't dropped out. They have an extension study within a placebo...and miraculously without a placebo the endpoints that were not stat sig with a placebo all the sudden are...laughable. So let me ask you a better question. If 100% of patients were taking a drug and 0% of them are getting a benefit, do you think people will still take it... probably...this is the U.S. which now has the stupidest population.
Market Data 
Markets 
AI
